"The groundwork of all happiness is health." - Leigh Hunt

A big review study found a lower risk of erectile dysfunction after prostate biopsy.

Having a prostate biopsy to envision for cancer is stressful, but fortunately the procedure comes with a low risk of unwanted effects. Infections could be reduced with antibiotics, and the discomfort and bleeding that some men experience often resolves quickly. An ongoing query is whether or not a biopsy can interfere with a person's ability to have an erection. Studies on this area have produced mixed results. But now the best A review of the evidence So far provides some encouraging news: According to the outcomes, men who lose a few of their libido after a biopsy often regain it inside a couple of weeks.

Why sexual dysfunction occurs after a biopsy just isn’t all the time clear. A biopsy needle can damage the nerves that control penile function, or the psychological stress of a cancer diagnosis can contribute to the issue. Erectile dysfunction can have a big impact on quality of life, so it is vital that doctors properly advise their patients on what to anticipate from the procedure.

During the review, investigators from King's College London identified greater than 6,000 studies that checked out the connection between prostate biopsy and sexual performance. They eventually reached the highest 54 studies with the perfect data. All of the lads in these studies filled out a questionnaire called the International Index of Erectile Function (IIEF-5), which assigns a rating based on a person's ability to develop and luxuriate in sexual intercourse. Is. The top rating—no erectile dysfunction—ranges from 22 to 25, while lower scores reflect mild, moderate, or more severe sexual problems.

The study's strongest result was a median decrease of 4.6 points in IIEF-5 scores, when measured one month after the procedure. But many men didn’t experience sexual unwanted effects, and in actual fact, the eight studies that included average values ​​found no significant difference in erectile function before or after prostate biopsy. As biopsies progressed, mean IEEF-5 scores continued to enhance. According to a King's College evaluation, scores obtained three months and 6 months after the biopsy were, on average, lower than one point lower than the scores obtained before the procedure.

The King's College investigators also investigated which features of the biopsy may increase the chance of erectile dysfunction. During this a part of the review, they noticed

  • Type of biopsy performed. Most men get a regular biopsy, which involves taking a sample of the prostate using a special needle inserted through the rectum. Others get a transperineal biopsy, which is finished by inserting a needle through the skin fold between the anus and the scrotum.
  • Number of tissue cores faraway from the prostate for analyses
  • Effects of anesthetics
  • Number of repeat biopsies over time.

As it turned out, the studies were so divided on these more specific questions that the investigators were unable to achieve any conclusions. They contended that whether any of those aspects increase the chance of biopsy-associated erectile dysfunction stays to be determined with clinical trials that track IIEF-5 scores over time.

So, what's the underside line? A big scientific review shows a big decrease in penile function one month after biopsy. But the authors emphasize that this effect — if it occurs — is temporary and unlikely to last.

“The data from this study provide some reassurance on sexual outcomes after a single prostate biopsy,” says Dr. Mark Garnick, Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. Harvard Medical SchoolAnnual Report on Diseases of the Prostateand Editor-in-Chief HarvardProstateKnowledge.org. “Some small studies have indicated that the risk of erectile dysfunction may increase with multiple prostate biopsies. In clinical practice, we reduce the actual number of biopsies performed by replacing prostate MRI scans. are trying to, especially in men being monitored for cancer progression on active surveillance.”